Understanding how UVB affects melanoma through immune signaling
Melanocyte PDL1 control of UVB-induced IFN-I
This study is looking at how a protein called melPDL1 affects melanoma cells when they are exposed to UVB light, using a special mouse model to help understand how this interaction might improve treatments for people with melanoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dartmouth-Hitchcock Clinic NIH-funded |
| Lab location | 1 site (Lebanon, United States) |
| Project ID | NIH-10943105 on NIH RePORTER |
What this research studies
This research investigates the role of a specific protein, melPDL1, in how melanoma cells respond to UVB radiation. By using a unique mouse model that mimics human melanoma, researchers will explore how UVB exposure influences immune responses and tumor progression. The study employs advanced techniques like single-cell sequencing and imaging to analyze the interactions between melanoma cells and the immune system. The goal is to uncover mechanisms that could lead to better treatments for melanoma patients.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with melanoma or those at high risk for developing melanoma due to UV exposure.
Not a fit: Patients with non-melanoma skin cancers or those without a history of UV exposure may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for enhancing immune responses against melanoma, potentially improving treatment outcomes.
How similar studies have performed: Previous research has shown promising results in understanding immune responses in melanoma, suggesting that this approach could yield valuable insights.
Where this research is happening
Lebanon, United States
- Dartmouth-Hitchcock Clinic — Lebanon, United States (Active)
Researchers
- Principal investigator: Curiel, Tyler J. — Dartmouth-Hitchcock Clinic
- Study coordinator: Curiel, Tyler J.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.